BMY at a glance
Bristol Myers Squibb (BMY, SEC CIK 14272) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Bristol Myers Squibb (BMY) reported revenue of $48.2 billion (down 0.2% from FY2024) and net income of $7.1 billion. Diluted EPS was $3.46.
- As of September 30, 2026, 62 institutional investment managers tracked by SignalX reported holding Bristol Myers Squibb (BMY) shares worth $50.6 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Haller Julia A on November 5, 2026 of 3,800 shares at $63.31 per share.
- In the last 90 days, BMY insiders reported 0 open-market purchases ($0) and 3 open-market sales ($678K) on Form 4, a net sale of $678K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $48.2B
- −0.2% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$678K
- 13F holders
- 62 funds
- $50.6B · +0 vs prior quarter
- Latest 8-K
- Oct 29, 2026
- Item 2.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model focused on oral immunomodulatory and oncology drugs, primarily treating multiple myeloma and CML
- FDA-approved volume-unlimited generics launched for Revlimid (2026), pomalidomide generics entering U.S. (Mar 2026), dasatinib generics active since Sept 2024
- Strategic shift marked by drastic revenue declines (up to 78% U.S. for Abraxane) due to generic erosion and Medicare Part D redesign
- Total expenses reduced 31% to $38.9B in 2025 driven by 72% drop in acquired IPRD spend and 14% SG&A cuts post productivity initiatives
- No excess inventory in U.S. distribution channels despite widespread generic competition, reflecting tightly managed supply and demand forecasting
Risk Factors
- FDA approval of Breyanzi in Dec 2025 for relapsed/refractory MZL after ≥2 systemic therapies, impacting market access and revenue
- Exposure to Japan's approval landscape with multiple key drug approvals by Ministry of Health Labour and Welfare in 2025, critical for Asia Pacific growth
- Dependence on strategic collaboration with BioNTech for co-development of pumitamig, a PD-L1/VEGF-A bispecific in oncology
- Competitive threat from BioNTech partnership leveraging innovative bispecific technology against IO market leaders Opdivo and Yervoy
- $2.0B expected cost savings by 2027 through expanded 2025 strategic productivity initiatives impacting R&D, manufacturing, and commercial functions
Management Discussion & Analysis
- Forward-looking: Management highlights multiple regulatory approvals, pipeline expansion via acquisitions and collaborations including Orbital Therapeutics and BioNTech, new radiopharmaceutical facility opened
AI summary of the BMY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $13,069 million, up 7% YoY from $12,222 million
- Effective tax rate 14.8% vs 29.5% YoY, non-GAAP EPS $1.35 vs $1.63
- Best product: Eliquis revenue $4,690 million, up 25% YoY; worst: Pomalyst/Imnovid, down 81%
- Operating cash flow $8.7 billion year-to-date vs $12.2 billion, net debt improved to $29.9 billion
- Headwinds: generic erosion, Eliquis price reduction, IRA pricing pressure, and potential further government price negotiations
Risk Factors
- No material changes from the risk factors disclosed in the 2025 Form 10-K
- Carried-forward risks include pharmaceutical regulatory approval and compliance exposure
- Carried-forward risks include product development and clinical trial uncertainty
- Carried-forward risks include competition and market pressures
- Carried-forward risks include liquidity, debt, and foreign currency exposures
AI summary of the BMY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 revenue $13.1B, up 7%, led by Growth Portfolio revenue of $7.7B, up 12%
- GAAP EPS $1.05 and non-GAAP EPS $1.35, each including a $(0.58) Acquired IPRD and licensing impact
Item EX-99.2: Item EX-99.2
- Q3 revenue $13.1B, up 7% year over year, with Growth Portfolio revenue $7.7B, up 12%
- Growth led by Eliquis $4.69B, up 25%, plus Camzyos $420M, up 42%, and Breyanzi $526M, up 46%
Item 2.02: Results of Operations and Financial Condition
- Bristol-Myers Squibb reported third-quarter 2026 financial results
- Earnings Press Release furnished as Exhibit 99.1, containing the detailed financial results and management commentary
Item 7.01: Regulation FD Disclosure
- Bristol Myers posted a presentation covering financial and operating initiatives for its third-quarter 2026 results webcast
- Materials support investor review of management’s Q3 2026 outlook, performance commentary and strategic priorities
Item EX-99.1: Item EX-99.1
- Q2 revenue $12.973B, up 6%; Growth Portfolio $7.560B, up 15%, offsetting Legacy Portfolio decline of 4%
- GAAP EPS $1.62, up 153%; non-GAAP EPS $2.04, up 40%, supported by lower amortization and tax expense
Item 2.02: Results of Operations and Financial Condition
- Bristol Myers Squibb announced second-quarter 2026 financial results on July 30, 2026
- Earnings Press Release furnished as Exhibit 99.1, containing the detailed financial results and management commentary
Item 7.01: Regulation FD Disclosure
- Q2 2026 financial-results presentation posted July 30, 2026, supporting the company’s earnings conference call
- Presentation covers financial and operating initiatives, with details available in Exhibit 99.2
Item 5.07: Submission of Matters to a Vote of Security Holders
- All 11 director nominees elected through the 2027 annual meeting, preserving board continuity
- Executive compensation approved with 1.459B votes for and 72.5M against
AI summaries of BMY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BMY
Don't miss the next BMY filing
- Alerts as it files. A push when BMY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BMY, by share count.
- Ask anything. An AI agent that reads every BMY filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Haller Julia A | Sell | Nov 5, 2026 | 3,800 | $63.31 |
| Lenkowsky Adam | M | Nov 3, 2026 | 7,522 | - |
| Lenkowsky Adam | M | Nov 3, 2026 | 7,522 | - |
| Lenkowsky Adam | F | Nov 3, 2026 | 3,848 | $61.71 |
| Shanahan Karin | M | Nov 1, 2026 | 6,281 | - |
| BOERNER CHRISTOPHER S. | J | Nov 1, 2026 | 406 | - |
| BOERNER CHRISTOPHER S. | F | Nov 1, 2026 | 1,724 | $62.48 |
| Meyers Gregory Scott | M | Nov 1, 2026 | 6,281 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $45.0B | $48.3B | $48.2B |
| Net Income | - | -$8.9B | $7.1B |
| Net Margin | - | -18.5% | 14.6% |
| Balance Sheet | |||
| Total Assets | $95.2B | $92.6B | $90.0B |
| Equity | $29.4B | $16.3B | $18.5B |
| ROE | - | -54.8% | 38.2% |
| Per Share | |||
| EPS | $3.86 | $-4.41 | $3.46 |
| Cash Flow | |||
| Operating CF | $13.9B | $15.2B | $14.2B |
| CapEx | $1.2B | $1.2B | $1.3B |
Source: XBRL data in Bristol Myers Squibb (BMY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BMY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 62 | $50.63B |
| Q2 2026 | 62 | $48.72B |
| Q1 2026 | 64 | $50.26B |
| Q4 2025 | 60 | $43.89B |
| Q3 2025 | 62 | $40.88B |
| Q2 2025 | 61 | $38.05B |
| Q1 2025 | 63 | $39.88B |
| Q4 2024 | 61 | $27.67B |
- Bank of America Corp+6.23M (+18%)
- Invesco Ltd+2.23M (+14%)
- Franklin Resources+1.86M (+39%)
- Millennium Management+1.45M (+193%)
- Goldman Sachs Group+1.07M (+6%)
- JPMorgan Chase & Co−11.50M (-16%)
- BlackRock−6.72M (-4%)
- T. Rowe Price Group−4.18M (-13%)
- Ameriprise Financial−2.79M (-10%)
- AQR Capital Management−2.47M (-9%)
- Bridgewater Associates LP+77.8K
- Renaissance Technologies LLC+18.2K
- Marex Group plc+5.1K
- FIRST MERCHANTS CORP+3.3K
- FMR LLC (Fidelity)−16.29M
- Equitable Holdings Inc−126.7K
- Blackstone Group−9.0K
- Northwest Bancshares, Inc.−5.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 495 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BMY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BMY SEC filings: frequently asked questions
Are BMY insiders buying or selling?
In the last 90 days, Bristol Myers Squibb (BMY) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $677,826 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BMY stock?
As of September 30, 2026, the largest Bristol Myers Squibb (BMY) holders among the 13F filers tracked by SignalX were BlackRock ($10.8 billion), Vanguard Capital Management LLC ($8.3 billion), State Street Corp ($6.4 billion), JPMorgan Chase & Co ($3.8 billion), Vanguard Portfolio Management LLC ($2.9 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BMY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Bristol Myers Squibb (BMY) reported revenue of $48.2 billion (down 0.2% from FY2024) and net income of $7.1 billion. Diluted EPS was $3.46. The figures come from the XBRL data in the 10-K.
What are the main risks in BMY's latest 10-K?
In the 10-K filed February 11, 2026, Bristol Myers Squibb (BMY) flagged: FDA approval of Breyanzi in Dec 2025 for relapsed/refractory MZL after ≥2 systemic therapies, impacting market access and revenue. Exposure to Japan's approval landscape with multiple key drug approvals by Ministry of Health Labour and Welfare in 2025, critical for Asia Pacific growth. (AI summary of the Risk Factors section.)
What did BMY report in its latest 8-K?
Bristol Myers Squibb (BMY) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 revenue $13.1B, up 7%, led by Growth Portfolio revenue of $7.7B, up 12%.
What are the latest BMY SEC filings?
Bristol Myers Squibb (BMY) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 6, 2026.
What is BMY's SEC CIK number?
Bristol Myers Squibb (BMY)'s SEC Central Index Key (CIK) is 14272. EDGAR lists every BMY filing under that number.
Ask anything about BMY
The research agent reads BMY's filings, financials, insider trades and 13F holders, then answers with sources.